LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
16 hedge funds and large institutions have $15.4M invested in LakeShore Biopharma in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
14% more funds holding
Funds holding: 14 → 16 (+2)
5.2% less ownership
Funds ownership: 6.41% → 1.2% (-5.2%)
25% less capital invested
Capital invested by funds: $20.4M → $15.4M (-$5.06M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$161K |
| 2 |
PCM
Prelude Capital Management
New York
|
+$47.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$33.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.6K |
| 5 |
HF
HRT Financial
New York
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLM
Snow Lake Management
Menlo Park,
California
|
-$2.15M |
| 2 |
RI
RTW Investments
New York
|
-$546K |
| 3 |
Millennium Management
New York
|
-$37K |
| 4 |
Jane Street
New York
|
-$19.2K |
| 5 |
CS
Clear Street
New York
|
-$160 |
LSB Hedge Fund Activity: Q2 2023 in Review
16 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q2 2023, worth a combined $15.4M — down 25% from $20.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LSB positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $161K. The largest seller was Snow Lake Management, cutting an estimated $2.15M.
- 16 institutional investors held LakeShore Biopharma (LSB) as of Q2 2023, up from 14 in Q1 2023.
- Funds reported $15.4M of LakeShore Biopharma stock for Q2 2023, down 25% quarter-over-quarter.
- 6 funds opened new LakeShore Biopharma positions in Q2 2023 and 4 closed out, a net change of +2 holders.
- The largest LakeShore Biopharma buyer in Q2 2023 was Barclays, an estimated $161K added.
- The largest LakeShore Biopharma seller in Q2 2023 was Snow Lake Management, an estimated $2.15M sold.
Based on aggregated 13F filings for Q2 2023.